Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma

We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Abidi, Muneer H., Gul, Zartash, Abrams, Judith, Ayash, Lois, Deol, Abhinav, Ventimiglia, Marie, Lum, Lawrence, Mellon-Reppen, Stephanie, Al-Kadhimi, Zaid, Ratanatharathorn, Voravit, Zonder, Jeffrey, Uberti, Joseph
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815645/
https://ncbi.nlm.nih.gov/pubmed/22759762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/1973947812Y.0000000004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak